Bertolotto A - Search Results

1

Is serum neopterin level a marker of responsiveness to interferon beta-1a therapy in multiple sclerosis?

Casoni F, Merelli E, Bedin R, Sola P, Bertolotto A, Faglioni P. Casoni F, et al. Among authors: bertolotto a. Acta Neurol Scand. 2004 Jan;109(1):61-5. doi: 10.1046/j.1600-0404.2003.00177.x. Acta Neurol Scand. 2004. PMID: 14653852 Clinical Trial.

2

Interferon beta neutralizing antibodies in multiple sclerosis: neutralizing activity and cross-reactivity with three different preparations.

Bertolotto A, Malucchi S, Milano E, Castello A, Capobianco M, Mutani R. Bertolotto A, et al. Immunopharmacology. 2000 Jul 20;48(2):95-100. doi: 10.1016/s0162-3109(00)00182-x. Immunopharmacology. 2000. PMID: 10936507

3

Interferon-beta (INF-beta) antibodies in interferon-beta1a- and interferon-beta1b-treated multiple sclerosis patients. Prevalence, kinetics, cross-reactivity, and factors enhancing interferon-beta immunogenicity in vivo.

Perini P, Facchinetti A, Bulian P, Massaro AR, Pascalis DD, Bertolotto A, Biasi G, Gallo P. Perini P, et al. Among authors: bertolotto a. Eur Cytokine Netw. 2001 Mar;12(1):56-61. Eur Cytokine Netw. 2001. PMID: 11282547 Free article.

4

Differential effects of three interferon betas on neutralising antibodies in patients with multiple sclerosis: a follow up study in an independent laboratory.

Bertolotto A, Malucchi S, Sala A, Orefice G, Carrieri PB, Capobianco M, Milano E, Melis F, Giordana MT. Bertolotto A, et al. J Neurol Neurosurg Psychiatry. 2002 Aug;73(2):148-53. doi: 10.1136/jnnp.73.2.148. J Neurol Neurosurg Psychiatry. 2002. PMID: 12122172 Free PMC article.

5

Necrotizing skin lesions and NABs development in a multiple sclerosis patient treated with IFNbeta 1b.

Casoni F, Merelli E, Bedin R, Martella A, Cesinaro A, Bertolotto A. Casoni F, et al. Among authors: bertolotto a. Mult Scler. 2003 Aug;9(4):420-3. doi: 10.1191/1352458503ms933sr. Mult Scler. 2003. PMID: 12926849

6

Neutralizing antibodies to interferon beta: implications for the management of multiple sclerosis.

Bertolotto A. Bertolotto A. Curr Opin Neurol. 2004 Jun;17(3):241-6. doi: 10.1097/00019052-200406000-00002. Curr Opin Neurol. 2004. PMID: 15167056 Review.

7

Immunogenicity of interferon beta: differences among products.

Bertolotto A, Deisenhammer F, Gallo P, Sölberg Sørensen P. Bertolotto A, et al. J Neurol. 2004 Jun;251 Suppl 2:II15-II24. doi: 10.1007/s00415-004-1204-7. J Neurol. 2004. PMID: 15264108 Review.

8

Measurement of neutralizing antibodies to interferon beta in patients with multiple sclerosis.

Deisenhammer F, Schellekens H, Bertolotto A. Deisenhammer F, et al. Among authors: bertolotto a. J Neurol. 2004 Jun;251 Suppl 2:II31-9. doi: 10.1007/s00415-004-1206-5. J Neurol. 2004. PMID: 15264110 Review.

9

Biological activity of interferon betas in patients with multiple sclerosis is affected by treatment regimen and neutralising antibodies.

Bertolotto A, Sala A, Malucchi S, Marnetto F, Caldano M, Di Sapio A, Capobianco M, Gilli F. Bertolotto A, et al. J Neurol Neurosurg Psychiatry. 2004 Sep;75(9):1294-9. doi: 10.1136/jnnp.2004.037259. J Neurol Neurosurg Psychiatry. 2004. PMID: 15314118 Free PMC article. Clinical Trial.

10

Biological responsiveness to first injections of interferon-beta in patients with multiple sclerosis.

Gilli F, Marnetto F, Caldano M, Sala A, Malucchi S, Di Sapio A, Capobianco M, Bertolotto A. Gilli F, et al. Among authors: bertolotto a. J Neuroimmunol. 2005 Jan;158(1-2):195-203. doi: 10.1016/j.jneuroim.2004.08.006. J Neuroimmunol. 2005. PMID: 15589054 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

377 results

Search Page

Filters